Latest Information Update: 20 Jul 2007
At a glance
- Originator ChemGenex Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action DNA repair enzyme inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 21 Jun 2004 AGT Biosciences has merged with ChemGenex Therapeutics Inc to form ChemGenex Pharmaceuticals
- 15 Apr 2002 Preclinical trials in Cancer in the US (unspecified route)